u/sofia_wikstrom

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

reflux at night, try not eating in the three hours before bed

Small fix — the shedding follows the rate of weight loss, not the compound, and it is temporary.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

Genuine question — is the appetite effect still there, or is it just the scale that has paused?

What dose and how many weeks at it before this started?

Severe or persistent abdominal pain sits outside the pattern this board can usefully discuss. The honest answer there is that it needs someone who can examine you.

Cosigning.

Right, and the timescale is the bit that keeps getting lost. Judge a step at a month, not at a weekend.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

open-label extensions are not the same evidence as the randomised phase

Which phase 2 arm are you quoting, and at what week?

The press release said that; the publication says something more hedged. Worth reading both.

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

Mine settled at week 5 and has not come back since, across two more steps.

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

I would be careful here. "Everyone gets this" is not true, and it makes the people who get something unusual assume they are fine when they should be asking.

Sceptical of the mechanism you are proposing. Gastric emptying slows, it does not stop, and the timings you describe do not follow from it.

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

nothing here is available as a prescription product, so read every thread with that in mind

a few kilos of drift is not a relapse

Been at maintenance for 15 months on 1.0mg. Nothing happens. That is the whole report and it took me a while to accept it as success.

Adding one thing — decide what maintenance looks like before you arrive at it.

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

a rough fortnight at each step is normal, a rough three months is not

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

dose day drift of a day either way is fine, the curve barely notices

the escalation is where most of the reported trouble sits

phase 2 finds a dose, phase 3 measures the effect

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

the food noise going quiet is the effect people came for, and early fullness is the toll for the first fortnight

Yes. Holding the dose is a real option and it does not mean you have failed at anything.

Kept a log specifically because there is so little published. It is one person and it is not data.

Dose reduction and interval extension are different interventions. Halving the dose keeps the rhythm and lowers the level; stretching keeps the level and lowers the frequency, with a lower trough.

Sceptical of the extrapolation.

titration_marshal is right about the escalation being the variable. It explains most of the difficult reports here.

Correction: TRIUMPH is the phase 3 programme.

This is the sentence the rest of the board should read first. Phase 2 is not a label.